Emend, Ivemend(fosaprepitant)
Emend, Ivemend (fosaprepitant) is a small molecule pharmaceutical. Fosaprepitant was first approved as Ivemend on 2008-01-11. It has been approved in Europe to treat neoplasms and vomiting. It is known to target substance-P receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Emend (generic drugs available since 2016-06-09)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fosaprepitant | New Drug Application | 2022-06-30 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
FOSAPREPITANT DIMEGLUMINE, EMEND, MERCK AND CO INC | |||
| 2025-05-02 | D-186 | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J1453 | Injection, fosaprepitant, 1 mg |
Clinical
Clinical Trials
62 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | HP_0002013 | R11.1 | 5 | 9 | 11 | 4 | 3 | 31 |
| Nausea | D009325 | HP_0002018 | R11.0 | 1 | 3 | 2 | 3 | 2 | 11 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | 1 | — | 2 | 2 | — | 5 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | 1 | 1 | — | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | 1 | — | 1 |
| Uterine neoplasms | D014594 | EFO_0003859 | C55 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 1 | 1 | 3 | — | — | 4 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 4 | — | — | 4 |
| Nasopharyngeal neoplasms | D009303 | 1 | — | 1 | — | — | 2 | ||
| Multiple myeloma | D009101 | C90.0 | 1 | 1 | 1 | — | — | 2 | |
| Female genital neoplasms | D005833 | — | — | 1 | — | — | 1 | ||
| Digestive system surgical procedures | D013505 | — | — | 1 | — | — | 1 | ||
| Uterine cervical neoplasms | D002583 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | — | 1 | ||
| Squamous cell carcinoma of head and neck | D000077195 | — | 1 | — | — | — | 1 | ||
| Squamous cell carcinoma | D002294 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Traumatic brain injuries | D000070642 | S06 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FOSAPREPITANT |
| INN | fosaprepitant |
| Description | Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.
|
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 |
Identifiers
| PDB | — |
| CAS-ID | 172673-20-0 |
| RxCUI | 1731071 |
| ChEMBL ID | CHEMBL1199324 |
| ChEBI ID | 64321 |
| PubChem CID | 219090 |
| DrugBank | DB06717 |
| UNII ID | 6L8OF9XRDC (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TACR1
TACR1
Organism
Homo sapiens
Gene name
TACR1
Gene synonyms
NK1R, TAC1R
NCBI Gene ID
Protein name
substance-P receptor
Protein synonyms
neurokinin receptor 1, NK-1 receptor, NK-1R, Tachykinin receptor 1, tachykinin receptor 1 (substance P receptor; neurokinin-1 receptor)
Uniprot ID
Mouse ortholog
Tacr1 (21336)
substance-P receptor (Q8BYR7)
Variants
Clinical Variant
No data
Financial
Emend - Merck Sharp & Dohme
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 520 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,594 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more